TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24641522
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate (CP) 0.05% ointment
Study: 24641522
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MMF) 0.1% ointment
Study: 22581482
Drug: Worry exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Worry exposure therapy (n = 29)
Study: 22581482
Drug: Applied relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied relaxation therapy (n = 27)
Study: 22581482
Drug: Post therapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post therapy (immediate outcome)
Study: 17653011
Drug: Ulinastatin (1000000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (1000000 U total dose)
Study: 2154314
Drug: Brachytherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brachytherapy alone or with external beam radiation therapy or surgery
Study: 2154314
Drug: Intraoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiation therapy
Study: 2154314
Drug: Hyperthermia with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermia with radiation therapy
Study: 2154314
Drug: Infusional (intravenous)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusional (intravenous) chemotherapy with radiation therapy
Study: 2154314
Drug: Intraarterial monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial monoclonal antibodies with radionuclides and intraarterial chemotherapy with radiation therapy
Study: 7357805
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% ophthalmic solution (2 drops to each eye with precautions)
Study: 7357805
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% ophthalmic solution (1 drop to each eye with no special precautions)
Study: 7357805
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% ophthalmic solution
Study: 22729611
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus multitargeted antiangiogenic TKI
Study: 14679127
Drug: Topotecan (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (1.5 mg/m(2)/day for 5 days)
Study: 14679127
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m(2)/day as a 3‐h infusion every 21 days)
Study: 11689808
Drug: Nitroglycerin (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (bolus injection of 2 mg)
Study: 9039301
Drug: Calcipotriol cream
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol cream (50 micrograms/g)
Study: 9039301
Drug: Betamethasone 17-valerate
Normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone 17-valerate cream (1 mg/g)
Study: 15037415
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing 3 mg of drospirenone + 30 microg of ethinyl estradiol (DRSP + EE)
Study: 11722416
Drug: Serum transferrin
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum transferrin receptor (sTfR) and TfR-Index
Study: 29073802
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (ST)
Study: 22276506
Drug: QRHX decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: QRHX decoction (composed of Huangbai, Chishao, Bixie, Danshen, Ezhu, Qingfengteng, raw Huangqi, Jinyinhua, Tufuling, Wugong, Fengfang, raw Yiyiren, cooked with water as 400 ml liquid)
Study: 19590482
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment (prednisolone 20 mg daily for 2 weeks followed by 10 mg daily for 2 weeks)
Study: 12632273
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with biweekly FOLFOX regimen (FOL: 500 mg/m2, F: 2000 mg/m2 for 2 days, OX: 85 mg/m2)
Study: 11108443
Drug: Local nasal
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local nasal immunotherapy (LNIT) with powder extract of Graminaceae or Parietaria pollens
Study: 11108443
Drug: Symptomatic pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic pharmacological treatment only (Control)
Study: 8601647
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg daily (21 patients)
Study: 8601647
Drug: Terbinafine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 500 mg daily for 1 week every month (21 patients)
Study: 8601647
Drug: Itraconazole 400
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 400 mg daily for 1 week every month (21 patients)
Study: 6463598
Drug: Thiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide (50 mg hydrochlorthiazide)
Study: 30802196
Drug: Intravenous sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sufentanil (1 μg/kg) and midazolam (0.2 mg/kg) (Group SM)
Study: 28619016
Drug: Endoscopic mask
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic mask oxygen-providing (3 L/min during intubation)
Study: 26974018
Drug: Rocuronium 1
Normalized name: rocuronium 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 1 mg/kg reversed with Sugammadex 2-4 mg/kg
Study: 26974018
Drug: Suxamethonium 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 1 mg/kg for induction, Rocuronium 0.3 mg/kg for maintenance, Neostigmine 0.03 mg/kg for reversal
Study: 23253641
Drug: Computerized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized cognitive behavioural therapy (cCBT)
Study: 23253641
Drug: Computer-administered attention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-administered attention placebo program with psychoeducational content (CPE)
Study: 19222417
Drug: No acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No acid regurgitation or epigastric pain pre-treatment
Study: 17470584
Drug: Daily Record
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Record of Severity of Problems (DRSP) scores using the standard method
Study: 17470584
Drug: Daily Record
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Record of Severity of Problems (DRSP) scores using the alternative method
Study: 11488789
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (ranitidine, colloidal bismuth subcitrate, metronidazole, and tetracycline)
Study: 7974072
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg trospectomycin sulfate i.m.
Study: 7974072
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ceftriaxone i.m.
Study: 30884170
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg s.c.
Study: 30884170
Drug: Anakinra 150
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 150 mg s.c.
Study: 30884170
Drug: Anakinra 300
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 300 mg s.c.
Study: 30884170
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg i.v.
Study: 28749480
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate at 10 mg kg‐1 day‐1, increased to 14 or 20 mg kg‐1 day‐1 BID at 36 weeks PMA
Study: 25516006
Drug: Ibuprofen/Famotidine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen/Famotidine combination
Study: 17048576
Drug: Integrative traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative traditional Chinese and Western medicine (ICWM) - Fufang Huangqi granule and lamivudine for at least 24 weeks
Study: 17048576
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) - Fufang Huangqi granule for at least 24 weeks
Study: 11113832
Drug: Outreach program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outreach program for young children with cerebral palsy (monthly training of parents with pictorial guidance manual)
Study: 11113832
Drug: Center-based mother-child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Center-based mother-child group (daily attendance)
Study: 8459913
Drug: Gadodiamide injection
Normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadodiamide injection (Gd-DTPA BMA), dosage: 0.1 mmol/kg body weight (0.2 ml/kg)
Study: 8459913
Drug: Gadopentetate dimeglumine
Normalized name: Gadopentetate Dimeglumine
DrugBank: Gadopentetic acid (DB00789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadopentetate dimeglumine (Gd-DTPA), dosage: 0.1 mmol/kg body weight (0.2 ml/kg)
Study: 29035068
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard therapy sessions)
Study: 9087484
Drug: dideoxyinosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dideoxyinosine (ddI) monotherapy
Study: 3512382
Drug: Tripotassium dicitrato
Normalized name: Tripotassium dicitratobismuthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripotassium dicitrato bismuthate (TDB) tablets
Study: 31856902
Drug: Treatment guided
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment guided by cerebral oxygenation monitoring
Study: 22986440
Drug: linaclotide 290
Normalized name: LINACLOTIDE 290MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: linaclotide 290 μg oral once daily
Study: 18720044
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (600 mg) followed by oral iron sulphate (200 mg daily from week 5)
Study: 18720044
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron sulphate (200 mg daily)
Study: 15932366
Drug: Trefoil factor
Normalized name: Trefoil Factor 2
DrugBank: Trefoil Factor 2 (DB15750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trefoil factor family‐3 enema (10 mg/mL)
Study: 10583036
Drug: Perindopril 4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4-8 mg once daily
Study: 30791771
Drug: Linaclotide (72
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linaclotide (72 µg, 145 µg, 290 µg)
Study: 27354646
Drug: Docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel plus Cisplatin (DP) - Docetaxel 70 mg/m²; Cisplatin 60 mg/m²; administered every 28 days
Study: 25065090
Drug: Kegel exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kegel exercise with concentration therapy
Study: 23247938
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg/wk
Study: 23247938
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every other week (EOW)
Study: 19430082
Drug: Daily iron-folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily iron-folate (IFA) supplementation (100 mg elemental iron + 0.5 mg folic acid daily for one year)
Study: 19430082
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly iron-folate (IFA) supplementation (100 mg elemental iron + 0.5 mg folic acid twice weekly for one year)
Study: 19430082
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly iron-folate (IFA) supplementation (100 mg elemental iron + 0.5 mg folic acid once weekly for one year)
Study: 12502652
Drug: HS glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS glucose >10 mmol/l
Study: 10475722
Drug: Thioridazine (Y:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (Y: 50 mg; O: 25 mg)
Study: 10475722
Drug: Remoxipride (Y:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (Y: 100 mg; O: 50 mg)
Study: 7104167
Drug: Drug with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug with non-linear release (NLR)
Study: 7104167
Drug: Drug with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug with linear release (LR)
Study: 7104167
Drug: Drug-free control
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free control
Study: 31825466
Drug: Mirtazapine 30
Normalized name: mirtazapine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 30 mg orally once daily for 24 weeks
Study: 30726969
Drug: Acipimox 250
Normalized name: acipimox 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 250 mg before oral glucose test
Study: 30726969
Drug: Acipimox 250
Normalized name: acipimox 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 250 mg before and during metabolic study
Study: 27821724
Drug: Autologous CD34+
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous CD34+ cells (minimum 10 mol/L±20% cells), N=78
Study: 21601248
Drug: Tamsulosin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin plus solifenacin 2.5 mg (TAM+SOL)
Study: 21601248
Drug: Tamsulosin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin plus solifenacin 5 mg (TAM+SOL)
Study: 16236919
Drug: Smoking reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking reduction with nicotine replacement therapy (nicotine gum and patch), required to reduce smoking by 25% for 2 weeks, 50% for 2 weeks, and 75% during the final 2 weeks.
Study: 8740120
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg twice daily for 3-5 days)
Study: 1833892
Drug: Enoximone 3
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 3 mg/kg orally
Study: 7042179
Drug: Pre‐operative radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐operative radiotherapy combined with daily intravenous fluorouracil during the first 4 days of irradiation followed by surgery (C)
Study: 15558726
Drug: Experimental vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental vaginal gel
Study: 15114295
Drug: Acute treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute treatment with 40 mg of ZnSO4 in a single dose
Study: 15114295
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with 100 mg ZnSO4 in a single dose daily for 7 days
Study: 23237616
Drug: Culturally and
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally and family tailored interventions to manage asthma symptoms; specific dosage and duration not applicable as this is qualitative data.
Study: 21036617
Drug: Stripping of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stripping of the posterior knee capsule (PCS)
Study: 21036617
Drug: No stripping
Approvals — FDA: no, EMA: no, PMDA: no
Description: No stripping of the posterior knee capsule (no-PCS)
Study: 17695792
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri Tablets (active treatment for 4 weeks)
Study: 17695792
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri Tablets (active treatment for 8 weeks)
Study: 15217515
Drug: Lymphatic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphatic chemotherapy (LC) - subcutaneous injection of 4 ml of carboplatin-activated carbon suspension (20 mg of carboplatin)
Study: 15217515
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy (VC) - intravenous administration of 20 mg of aqueous carboplatin
Study: 11231856
Drug: Steroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid group (500 mg of methylprednisolone administered intravenously 2 hours before surgery)
Study: 9670258
Drug: Intraoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiotherapy (IORT) plus external beam radiotherapy (EBRT) with concomitant chemotherapy (5-FU, leucovorin)
Study: 7758398
Drug: L-carnitine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (4 g or 2 g) with 10% or 5% glucose infusion
Study: 7758398
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10% or 5% glucose infusion without L-carnitine)
Study: 2455778
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with vinblastine for 6 months
Study: 2455778
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (cisplatin, vinblastine, and bleomycin)
Study: 30799192
Drug: Serum albumin
Normalized name: Serum albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum albumin levels <51.4 g/L
Study: 30799192
Drug: Serum albumin
Normalized name: Serum albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum albumin levels ≥51.4 g/L
Study: 30799192
Drug: Serum albumin
Normalized name: Serum albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum albumin levels <51.4 g/L without proteinuria
Study: 19441668
Drug: Escitalopram (n=51,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (n=51, 10-20 mg/day)
Study: 19441668
Drug: Nortriptyline (n=39,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (n=39, 75-150 mg/day)
Study: 14728846
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metformin and compound cyproterone acetate (CPA) (group A3)
Study: 14728846
Drug: Metformin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin alone (group A2)
Study: 14728846
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metformin and CPA (group A3)
Study: 10775075
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) therapy
Study: 8839730
Drug: Reformulated Oka
Normalized name: Tarsum Reformulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated Oka strain varicella vaccine
Study: 6695658
Drug: Verapamil, 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil, 7.5 mg intravenously
Study: 30037480
Drug: Reminder letters
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reminder letters sent to parents or guardians of eligible adolescents due for the first dose of HPV vaccine.
Study: 24905296
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg daily for 6 months
Study: 22920048
Drug: Olmesartan medoxomil/hydrochlorothiazide
Normalized name: olmesartan medoxomil/hydrochlorothiazide 40 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan medoxomil/hydrochlorothiazide (OM/HCTZ) 40 mg/25 mg
Study: 22920048
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (OM) 20 mg daily to OM 40 mg
Study: 17602170
Drug: Blueberry/apple juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry/apple juice providing 97 mg quercetin and 16 mg ascorbic acid a day
Study: 15074091
Drug: Pushen capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pushen capsule (PSC) (4 capsules, tid)
Study: 15074091
Drug: Zhibituo tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhibituo tablet (3 tablets, tid)
Study: 11677003
Drug: Gabapentin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1200 mg, administered three times daily for 12 months)
Study: 334220
Drug: Nomifensine 50
Normalized name: nomifensine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomifensine 50 mg
Study: 30606789
Drug: Warfarin (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (18 months treatment after initial 6 months)
Study: 30606789
Drug: Placebo (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (18 months treatment after initial 6 months)
Study: 30606789
Drug: Warfarin (42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (42 months total follow-up)
Study: 24613094
Drug: Estradiol ≥30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol ≥30 ng/mL with percent mean body weight
Study: 1980415
Drug: Promazin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promazin (1.0 mg/kg)
Study: 1980415
Drug: Promethazin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazin (1.0 mg/kg)